Facebook
Instagram
Linkedin
Youtube
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Search
BioStock
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Home
Search
elicera
-
search results
If you're not happy with the results, please do another search
Elicera’s CEO: “ELC-100 stands apart from all other standard treatments”
27 November, 2024
Another successful summit – watch all videos here
22 November, 2024
Elicera’s CEO: “One of the biggest milestones in our history”
12 November, 2024
Investing in life science: From Seed to Success 2024
16 September, 2024
Elicera teams up with China Medical University for cancer study
17 June, 2024
BioStock Global Forum 2024
3 June, 2024
Elicera’s first clinical CAR T-Cell study CARMA set to begin
29 May, 2024
Elicera collaborates with US cancer centre to evaluate iTANK
7 March, 2024
Full speed ahead for Elicera in 2024
19 February, 2024
Elicera gets green light for CAR T clinical study
14 February, 2024
FDA CAR T investigation does not affect Elicera
21 December, 2023
CAR T deal puts spotlight on Elicera’s technology
29 November, 2023
Elicera’s CEO: ” iTANK has great potential in treating solid tumours”
16 November, 2023
All sessions from BioStock Life Science Fall Summit 2023
30 October, 2023
Video from day 2 of BioStock Life Science Fall Summit 2023
27 October, 2023
Interviews from LSX Nordic Congress
11 October, 2023
Elicera’s potential in cancer therapy published in Nature Communications
15 August, 2023
Elicera Therapeutics receives important EU patent
13 July, 2023
Elicera gives an update in Cancer Immunotherapy Month
30 June, 2023
The BioStock Life Science Spring Summit 2023 goes live today
30 May, 2023
Well-financed Elicera prepared for clinic and business development
24 May, 2023
Janssen CAR T deal supports Elicera’s vision
10 May, 2023
BioStock Life Science Summit May 2023
5 April, 2023
Elicera on CAR T-cells’ potential beyond blood cancer
30 March, 2023
BioStock Life Science Summit 2023
20 March, 2023
Advancements for Elicera in 2022 open for intensive clinical year
23 February, 2023
Strong AstraZeneca sees continued growth
14 February, 2023
Elicera on AstraZeneca’s acquisition of Neogene Therapeutics
8 February, 2023
The CAR T revolution in the fight against cancer
2 February, 2023
Elicera on the positive clinical effect in cancer trial
15 December, 2022
Elicera’s CEO: “iTANK partnering is intensifying”
22 November, 2022
Elicera Therapeutics enters first international collaboration involving iTANK
19 October, 2022
NLSDays: Interviews with 10 interesting companies
6 October, 2022
BioStock Investor Meeting: Interview with Elicera Therapeutics
27 September, 2022
BioStock Investor Meeting: Elicera Therapeutics presents
20 September, 2022
Elicera Therapeutics strengthens financial standing in Q2
30 August, 2022
BioStock Investor Meeting, September 14
15 August, 2022
Elicera receives funding for clinical trials with ELC-301
3 June, 2022
Elicera continues to deliver proof-of-concept data
29 April, 2022
BioStock Studio: Elicera’s immuno-oncology platform iTANK reaches high-impact journal
6 April, 2022
Elicera well-positioned to thrive in 2022
20 January, 2022
Elicera Therapeutics partners with Baylor College of Medicine
17 December, 2021
Elicera Therapeutics keeps strong momentum after IPO
24 November, 2021
Elicera Therapeutics enters agreement with BioNTech
12 November, 2021
Elicera Therapeutics’ iTANK-platform reaches proof-of-concept
20 October, 2021
Elicera Therapeutics comes out of the gate running in Q2
31 August, 2021
Successful new share issue provides tailwinds for Elicera Therapeutics
28 June, 2021
Elicera receives ATMP classification from EMA
28 June, 2021
Status report Elicera Therapeutics – Pushing the boundaries of immuno-oncology
2 June, 2021
BioStock Live with Elicera Therapeutics
31 May, 2021
BMS CAR T-cell approval: Elicera sees an opening
15 April, 2021
Elicera Therapeutics takes immuno-oncology to the next level
2 March, 2021
